910267--3/5/2007--TITAN_PHARMACEUTICALS

related topics

{stock, price, share}

{product, candidate, development}

{stock, price, operating}

{product, liability, claim}

{control, financial, internal}

{personnel, key, retain}

{property, intellectual, protect}

{regulation, government, change}

{acquisition, growth, future}

We have a history of operating losses and may never be profitable. Our products are at various stages of development and may not be successfully developed or commercialized. We must comply with extensive government regulations. We face risks associated with third parties conducting preclinical studies and clinical trials of our products as well as our dependence on third parties to manufacture any products that we may successfully develop. We face many uncertainties relating to our human clinical trial strategy and results. We face risks associated with clinical trial liability claims in the event that the use or misuse of our product candidates results in personal injury or death. We may be unable to protect our patents and proprietary rights. We are dependent upon our key collaborative relationships and license and sponsored research agreements. We must meet payment and other obligations under our license and sponsored research agreements. We may be dependent upon third parties to manufacture and market any products we successfully develop. Healthcare reform and restrictions on reimbursements may limit our financial returns. We may not be able to retain our key management and scientific personnel. We will need additional financing. Future sales of our common stock in the public market could adversely impact our stock price. Our stock price has been and will likely continue to be volatile. The market price of our common stock may fluctuate in a way that is disproportionate to our operating performance. Cornell Capital Partners may sell shares of our common stock after we deliver a draw-down notice during the pricing period, which could cause our stock price to decline. Sales of our shares of common stock under the Standby Equity Distribution Agreement could result in significant dilution to the existing shareholders. Sales of our stock under the Standby Equity Distribution Agreement could encourage short sales by third parties which could contribute to the future decline of our stock price. We may not be able to make a draw-down under the Standby Equity Distribution Agreement if Cornell Capital Partners holds more than 9.9% of our common stock. We will not be able to make a draw-down under the Standby Equity Distribution Agreement if we would be required to issue more than 6,475,287 shares of our common stock unless we obtain stockholder approval for such issuance. (a) Price Range of Securities (b) Approximate Number of Equity Security Holders

Full 10-K form ▸

910267--3/5/2007--TITAN_PHARMACEUTICALS_INC